Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other Non-Current Assets (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Other Non-Current Assets for 16 consecutive years, with $871000.0 as the latest value for Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 41.93% year-over-year to $871000.0; the TTM value through Sep 2025 reached $871000.0, down 41.93%, while the annual FY2024 figure was $879000.0, 30.51% down from the prior year.
  • Other Non-Current Assets hit $871000.0 in Q3 2025 for Sangamo Therapeutics, down from $890000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $17.4 million in Q2 2023 and bottomed at $871000.0 in Q3 2025.
  • Average Other Non-Current Assets over 5 years is $5.7 million, with a median of $1.5 million recorded in 2021.
  • Year-over-year, Other Non-Current Assets skyrocketed 974.2% in 2022 and then plummeted 91.28% in 2023.
  • Sangamo Therapeutics' Other Non-Current Assets stood at $15.3 million in 2021, then plummeted by 90.21% to $1.5 million in 2022, then fell by 15.67% to $1.3 million in 2023, then plummeted by 30.51% to $879000.0 in 2024, then decreased by 0.91% to $871000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $871000.0, $890000.0, and $882000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.